000			01507 a2200409 4500
005			20250513104816.0
264		0	_c19970313
008			199703s 0 0 eng d
022			_a0197-2456
024	7		_a10.1016/s0197-2456(95)00259-6 _2doi
040			_aNLM _beng _cNLM
100	1		_aSiegel, C
245	0	0	_aStatistical methods for cost-effectiveness analyses. _h[electronic resource]
260			_bControlled clinical trials _cOct 1996
300			_a387-406 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, U.S. Gov't, P.H.S.
650	0	4	_aAntipsychotic Agents _xtherapeutic use
650	0	4	_aConfidence Intervals
650	0	4	_aCost-Benefit Analysis _xstatistics & numerical data
650	0	4	_aDrug Evaluation _xstatistics & numerical data
650	0	4	_aHealth Care Costs _xstatistics & numerical data
650	0	4	_aHealth Services Research _xstatistics & numerical data
650	0	4	_aHumans
650	0	4	_aLikelihood Functions
650	0	4	_aModels, Statistical
650	0	4	_aMultivariate Analysis
650	0	4	_aQuality-Adjusted Life Years
650	0	4	_aRegression Analysis
650	0	4	_aResearch Design
650	0	4	_aSchizophrenia _xdrug therapy
650	0	4	_aStatistics, Nonparametric
650	0	4	_aSurvival Analysis
700	1		_aLaska, E
700	1		_aMeisner, M
773	0		_tControlled clinical trials _gvol. 17 _gno. 5 _gp. 387-406
856	4	0	_uhttps://doi.org/10.1016/s0197-2456(95)00259-6 _zAvailable from publisher's website
999			_c8925379 _d8925379